Specific gene that could be responsible for
metabolic diseases
We are all familiar with the dangers of too much fat in our
diet--increased risk of diabetes, heart disease, and obesity
are just a few of the most severe consequences.
But some rare metabolic diseases, such as hypolipidemia and
Tangier disease, seem to work in reverse--they severely
limit the amount of fat and cholesterol that makes it into
the bloodstream. Researchers from the Carnegie Institution
and the University of Pennsylvania have found a specific
gene that could be responsible for such conditions; when the
gene is disrupted, so is the ability to absorb lipids (fatty
substances that include cholesterol) through the intestine.
In their latest research, published in the April 4 issue of
the journal Cell Metabolism, Steve Farber of Carnegie's
Department of Embryology and Michael Pack, of the University
of Pennsylvania School of Medicine describe their efforts to
locate a gene called fat free within the genome of the
zebrafish. These fish have become popular research organisms
because their embryos are transparent, allowing studies that
are not possible with traditional model organisms, such as
mice and rats. Farber and Pack found that, despite the
distant evolutionary relation between humans and zebrafish,
the fat free gene in zebrafish is quite similar to a pair of
human genes.
The researchers also explore the physical effects of a
specific mutation of the gene, seeking to explain why larval
fish with the mutation exhibit an impaired ability to absorb
cholesterol. These fish die when they are about a
one-and-a-half weeks old because of this defect, even though
they look normal and swallow properly.
"There is a lot we still don't know about how animals
absorb, transport, and otherwise manage lipids," Farber
said. "The fact that just one gene can have such a huge
effect is encouraging, because it might reveal a means for
treatment of human disease."
The scientists began by looking for structural defects in
the mutants' digestive organs. Their livers have
abnormalities in the cells and ducts that produce bile--a
salty, somewhat soapy fluid that helps lipid digestion.
Certain pancreatic cells are also flawed, interfering with
the production of digestive enzymes necessary for the
breakdown of complex lipid molecules.
More importantly, the mutants also have defects in the cells
that line the intestine, where fat and cholesterol
absorption takes place. Normally, globules of lipid pass
into these cells in small sacs called vesicles. These
vesicles connect with the Golgi apparatus, a labyrinth of
membranes filled with enzymes that modify the fats, and then
new vesicles transport the fats out of the cell and into the
bloodstream. The researchers found that this process is
disrupted in the fat free mutants, preventing fats from
reaching the bloodstream, and thereby depriving the animal
of needed lipids.
Farber and Pack used a strategy called positional cloning
both to locate fat free in the zebrafish genome and to
determine its sequence. They found that the gene shares 75
percent of its sequence with a human gene called ANG2
(Another New Gene 2), which up to this time has had no known
function. It also shares parts of its sequence with a gene
called COG8, which is known to affect the Golgi apparatus.
They also found that a change in only one base--one "letter"
in the DNA code--results in the lethal mutation in zebrafish.
"This gene is absolutely necessary for cholesterol
absorption--without it, the animals die," Farber said. This
is encouraging for Pack, a physician-scientist in Penn's
Department of Medicine, "If we can understand this process
in zebrafish, perhaps we can take what we learn and apply it
to similar genes in humans, which could in turn lead to
treatment for lipid metabolism disorders."